封面
市场调查报告书
商品编码
1541332

2024-2032 年按药物类别、产品类型、应用、最终用户和地区分類的促红血球生成素药物市场报告

Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032

出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球促红血球生成素药物市场规模达110亿美元。贫血和癌症盛行率不断上升、慢性肾臟病治疗应用的增加以及大众对该药物潜在影响的认识不断提高,是推动市场发展的一些关键因素。

促红血球生成素 (EPO) 药物包括各种药物,例如促红血球生成素-α、红血球生成素-β 和达贝泊汀-α,用于治疗体内 EPO 缺乏症。它们是使用重组脱氧核糖核酸 (DNA) 技术合成製造的。它们刺激骨髓中红血球(RBC)的产生并调节体内血红素的浓度。它们有助于增强耐力、减少疲劳、增加新陈代谢和改善肌肉的癒合过程,同时保持体内红血球的健康数量。它们用于治疗个体之间的各种疾病,例如贫血、末期肾病、人类免疫缺陷病毒(HIV)和血液疾病。除此之外,运动员服用 EPO 药物可以提高他们的表现和有氧能力,因为它们有助于增加肌肉的氧气供应。

促红血球生成素药物市场趋势:

目前,由于个体中癌症和神经系统疾病,如自闭症、脑肿瘤、脑性麻痹、癫痫、注意力缺陷障碍(ADD)的盛行率不断上升,群众对EPO药物的需求不断增加,这是关键之一。除此之外,大众对 EPO 药物及其有效性的认识不断提高,这提供了积极的市场前景。此外,世界各地群众对外科手术介入的需求也在增加。再加上越来越多地使用 EPO 药物来减少患者手术后的同种异体输血,正在推动市场的成长。除此之外,全球范围内慢性肾病(CKD)病例数量的不断增加为行业投资者提供了利润丰厚的成长机会。此外,EPO 药物提供的各种益处,例如增加红血球 (RBC) 和减轻疲劳,正在对市场产生积极影响。除此之外,世界各地促红血球生成素生物相似药的快速商业化正在推动市场的成长。再加上全球对生物相似药而非参考药的日益青睐,正在推动市场的成长。此外,研究机构越来越多地将 EPO 药物作为新型治疗剂用于众多研究目的,这正在加强市场的成长。

本报告回答的关键问题

  • 全球促红血球生成素药物市场有多大? 2024-2032年全球促红血球生成素药物市场的预期成长率为何?
  • 推动全球促红血球生成素药物市场的关键因素是什么?
  • COVID-19对全球促红血球生成素药物市场有何影响?
  • 根据药物类别,全球促红血球生成素药物市场的细分如何?
  • 根据产品类型,全球促红血球生成素药物市场的细分如何?
  • 根据应用,全球促红血球生成素药物市场的细分情况如何?
  • 根据最终用户,全球促红血球生成素药物市场的细分情况如何?
  • 全球促红血球生成素药物市场的重点区域有哪些?
  • 全球促红血球生成素药物市场的主要参与者/公司有哪些?

目录

第一章:前言

第 2 章:范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章:执行摘要

第 4 章:简介

  • 概述
  • 主要行业趋势

第 5 章:全球促红血球生成素药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章:市场区隔:依药物类别

  • 生物製剂
    • 市场趋势
    • 市场预测
  • 生物相似药
    • 市场趋势
    • 市场预测

第 7 章:市场区隔:依产品类型

  • 阿尔法依泊汀
    • 市场趋势
    • 市场预测
  • β-促红血球生成素
    • 市场趋势
    • 市场预测
  • 达贝泊汀-阿尔法
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章:市场区隔:按应用

  • 血液学
    • 市场趋势
    • 市场预测
  • 肾臟疾病
    • 市场趋势
    • 市场预测
  • 癌症
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章:市场区隔:按最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 居家护理
    • 市场趋势
    • 市场预测
  • 专科诊所
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章:市场区隔:按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分:按国家/地区
    • 市场预测

第 11 章:SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章:价值链分析

第 13 章:波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章:价格分析

第15章:竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Biocon Limited
    • Dr. Reddy's Laboratories Ltd.
    • F. Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • Johnson & Johnson
    • LG Chem Ltd.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A4270

The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends:

At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.

Drug Class Insights:

Biologics

Biosimilars

The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

Hematology

Kidney Disorder

Cancer

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global erythropoietin drugs market?
  • 2. What is the expected growth rate of the global erythropoietin drugs market during 2024-2032?
  • 3. What are the key factors driving the global erythropoietin drugs market?
  • 4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
  • 5. What is the breakup of the global erythropoietin drugs market based on the drug class?
  • 6. What is the breakup of the global erythropoietin drugs market based on the product type?
  • 7. What is the breakup of the global erythropoietin drugs market based on the application?
  • 8. What is the breakup of the global erythropoietin drugs market based on the end-user?
  • 9. What are the key regions in the global erythropoietin drugs market?
  • 10. Who are the key players/companies in the global erythropoietin drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Erythropoietin Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Biologics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biosimilars
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Epoetin-alfa
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Epoetin-beta
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Darbepoetin-alfa
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hematology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Kidney Disorder
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Specialty Clinics
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Biocon Limited
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Dr. Reddy's Laboratories Ltd.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Intas Pharmaceuticals Ltd.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 LG Chem Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sun Pharmaceutical Industries Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Erythropoietin Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Erythropoietin Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Erythropoietin Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Erythropoietin Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Erythropoietin Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 6: Global: Erythropoietin Drugs Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Erythropoietin Drugs Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Erythropoietin Drugs Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Erythropoietin Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Erythropoietin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Erythropoietin Drugs (Biosimilars) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Erythropoietin Drugs (Biosimilars) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Erythropoietin Drugs (Epoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Erythropoietin Drugs (Epoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Erythropoietin Drugs (Epoetin-beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Erythropoietin Drugs (Epoetin-beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Erythropoietin Drugs (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Erythropoietin Drugs (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Erythropoietin Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Erythropoietin Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Erythropoietin Drugs (Kidney Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Erythropoietin Drugs (Kidney Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Erythropoietin Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Erythropoietin Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Erythropoietin Drugs (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Erythropoietin Drugs (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Erythropoietin Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Erythropoietin Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Erythropoietin Drugs (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Erythropoietin Drugs (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Erythropoietin Drugs (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Erythropoietin Drugs (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Erythropoietin Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Erythropoietin Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Erythropoietin Drugs Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Erythropoietin Drugs Industry: SWOT Analysis
  • Figure 87: Global: Erythropoietin Drugs Industry: Value Chain Analysis
  • Figure 88: Global: Erythropoietin Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Erythropoietin Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Erythropoietin Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Erythropoietin Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 4: Global: Erythropoietin Drugs Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Erythropoietin Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Erythropoietin Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Erythropoietin Drugs Market: Competitive Structure
  • Table 8: Global: Erythropoietin Drugs Market: Key Players